Table 1.
Health and medical conditions recommended for cannabis treatment on 179 identified websites and corresponding conclusions from the National Academies 2017 review
| Condition | Percent | NASEM conclusion |
|---|---|---|
| Nausea (including from chemotherapy) | 26 | Conclusive or substantial |
| Pain | 24 | (no conclusion) |
| Epilepsy | 23 | None or insufficient |
| Multiple sclerosis | 21 | Conclusive or substantial |
| Chronic pain | 20 | Conclusive or substantial |
| Anxiety | 20 | Limited |
| Appetite loss | 19 | Limited |
| Cancer | 19 | None or insufficient |
| Glaucoma/Intraocular pressure | 15 | Ineffective (limited) |
| Depression | 14 | Ineffective (limited) |
| Vomiting (including from chemotherapy) | 14 | Conclusive or substantial |
| Chronic Fatigue Syndrome | 13 | (no conclusion) |
| Insomnia | 13 | (no conclusion) |
| PTSD | 13 | Limited |
| Neuropathic pain | 11 | (no conclusion) |
| Arthritis (including various forms) | 10 | (no conclusion) |
| Inflammation | 10 | Limited |
| HIV/AIDS | 10 | None or insufficient |
| Muscle spasms | 10 | (no conclusion) |
| Drug and alcohol addiction | 9 | Increased risk (moderate) |
Note: NASEM Conclusion indicates determinations by the National Academies of Sciences, Engineering, and Medicine (2017) that there is conclusive or substantial evidence that cannabis or cannabinoids are effective in treatment, conditions for which evidence for effectiveness was limited, conditions with no or insufficient evidence for treatment effectiveness (9%), conditions with evidence for the ineffectiveness of treatment, and conditions with evidence for increased risk due to the use of cannabis